Глобальный рынок тестирования на внутрибольничные заболевания – тенденции отрасли и прогноз до 2030 года

Анализ и размер рынка тестирования на внутрибольничные заболевания

Растущее число пациентов, страдающих от внутрибольничных инфекций, растущее число правительственных постановлений по наказанию больниц, длительная госпитализация и резистентность антител, рост индустрии медицинского туризма и распространенность модернизированной инфраструктуры здравоохранения являются одними из основных и влиятельных факторов, которые, вероятно, будут способствовать росту рынка тестирования на внутрибольничные заболевания в прогнозируемый период 2023-2030 гг. С другой стороны, развитие различных технологий и увеличение числа научно-исследовательских и опытно-конструкторских работ различными компаниями предоставят многочисленные возможности, что приведет к росту рынка тестирования на внутрибольничные заболевания в прогнозируемый период.

По данным Data Bridge Market Research, рынок тестирования на заболевания, приобретенный больницами, который в 2022 году составил 10,3 млрд долларов США, как ожидается, достигнет 35,92 млрд долларов США к 2030 году при среднегодовом темпе роста 16,90% в прогнозируемый период с 2023 по 2030 год. Помимо информации о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, подготовленные Data Bridge Market Research, также включают в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ воронки поставок, анализ цен и нормативную базу.

Масштаб и сегментация рынка тестирования на внутрибольничные заболевания  

Market Definition

Health care professionals, particularly clinical laboratory technicians, use hospital acquired disease testing to diagnose nosocomial infection. Healthcare professionals, particularly clinical laboratory technicians, use hospital acquired disease testing to diagnose nosocomial infections. The hospital acquired infection testing market has grown rapidly over the last decade, owing to factors such as increased awareness about the global increase in the incidence of nosocomial infections and the development of innovative prevention and treatment solutions.

Hospital Acquired Disease Testing Market Dynamics

Drivers

• Growing prevalence of HAIs

The market for hospital acquired disease testing is currently growing at a double-digit rate. The global number of health care facilities has increased significantly as a result of rising population and modernization of healthcare infrastructure. As a result, the prevalence of HAIs has increased, increasing the demand for hospital acquired disease tests. Furthermore, with advanced technologies and scientific innovations, various techniques for diagnosing, preventing,  and monitoring HAIs, such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs) and solid phase hybridization, are now available on the market. Techniques like RTLS make it simple to keep HAIs from spreading among patients and staff. These are the certain factors which propel the market growth.

• Rise in the number of drug resistant pathogens

Rapid and efficient infection detection solutions help reduce the incidence of nosocomial infections and overall medical costs, hospital stays, and death. The widespread availability of more sophisticated infection detection solutions, particularly those under molecular diagnostics, as well as their demonstrated efficiency in delivering faster results, has increased demand for such products worldwide. Demand for hospital acquired government initiatives are driving infection testing and hospital acquired infection controlling authorities focusing on spreading awareness about hospital acquired infection and available treatments. As a result, the rise in drug-resistant pathogens and the prevalence of hospital acquired infections are driving the growth of the hospital acquired infection testing market.

Opportunities

• Establishment of government guidelines

According to the US Department of Health and Human Services, hospital acquired infection prevention costs between $28.0 billion and $33.0 billion per year. Governments are taking steps to reduce hospital acquired infection prevalence in their respective countries in order to reduce the burden on hospitals caused by patients' prolonged hospital stays. Hospital acquired infection prevention and control authorities exist in developed countries, with established guidelines for detection and treatment of hospital acquired infection. For instance, the Centers for Disease Control and Prevention (CDC), recommends a nucleic acid amplification test for C. difficile detection, whereas the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommends a two-step detection process for C. difficile identification. In countries, these guidelines drive the market for recommended tests.

Restraints/Challenges

• Stringent regulations and guidance framework

Stringent government regulations regarding molecular biology-based diagnostics and a lack of awareness among people in developing economies are likely to act as market restraints in the growth of hospital acquired disease testing during the forecast period.

This hospital acquired disease testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hospital acquired disease testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Hospital Acquired Disease Testing Market Scope

The hospital acquired disease testing market is segmented on the basis of test type and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

• Urinary Tract Infection
• Surgical Site Infection
• Pneumonia Stents
• Blood Stream Infection
• Methicillin-Resistant Staphylococcus Aureus
• Others

 End User

• Hospitals and Intensive Care Units (ICUS)
• Ambulatory Surgical and Diagnostic Centers
• Nursing Homes
•  Maternity Centers

Hospital Acquired Disease Testing Market Regional Analysis/Insights

The hospital acquired disease testing market is analyzed and market size insights and trends are provided by country, test type and end user as referenced above.

The countries covered in the hospital acquired disease testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the hospital acquired disease testing market due to an increase in the number of government initiatives aimed at reducing nosocomial infections, as well as the prevalence of favourable reimbursement policies in the region as a result of the growth of medical tourism.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the increase in the number of hospitals and the occurrences of hospital acquired infections.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The hospital acquired disease testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for hospital acquired disease testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the hospital acquired disease testing market. The data is available for historic period 2011-2021.

Competitive Landscape and Hospital Acquired Disease Testing Market Share Analysis

The hospital acquired disease testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hospital acquired disease testing market.

Некоторые из основных игроков, работающих на рынке тестирования на внутрибольничные заболевания:

• Эбботт (США)
• Eurofins Scientific (Люксембург)
• БИОМЕРЬЕ (Франция)
• Cantel Medical (США)
• Meridian Bioscience, Inc. (США)
• QIAGEN (Германия)
• F. Hoffmann-La Roche Ltd (Швейцария)
• БД (США)
• Hologic, Inc. (США)
• Siemens Healthcare Private Limited (Германия)
• Thermo Fisher Scientific Inc. (США)
• Medtronic (Ирландия)
• Getinge AB (Швеция)
• Корпорация Olympus (Япония)
• 3M (США)
• Корпорация Luminex (США)
• Лаборатории Диатерикс (США)
• Life Technologies (США)
• Cepheid Inc. (США)

SKU-57291